WALTHAM, Mass.--(BUSINESS WIRE)--NeurAxon Inc., a developer of next-generation pain therapeutics, today announced the appointment of David Brand to the Company’s Board of Directors. Mr. Brand was most recently President and Chief Executive Officer of Cardiokine, Inc., where he led strategic and organizational development, multiple private financings and most recently a significant co-development and commercialization agreement with Biogen Idec. He also serves on the Board of Directors at InteKrin Therapeutics, Inc.
